Home/Pipeline/ALS Research (post-RADICAVA)

ALS Research (post-RADICAVA)

Amyotrophic Lateral Sclerosis

Preclinical/ResearchActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis

Phase

Preclinical/Research

Status

Active

Company

Tanabe Pharma America

About Tanabe Pharma America

Tanabe Pharma America is a U.S.-based pharmaceutical company established in 2017 as the American arm of the long-standing Japanese firm Tanabe Pharma Corporation. The company is in the commercial and late-stage clinical development stage, with a marketed product for ALS (RADICAVA/edaravone, recently transferred) and a late-phase pipeline asset, dersimelagon, for rare photodermatoses. TPA's strategy centers on advancing small molecule therapies for severe neurological and rare diseases, building on its parent company's extensive R&D heritage. It operates as a private, revenue-generating entity, though specific financials are not disclosed.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis Parkinson's Disease Erythropoietic Protoporphyria X-Linked Protoporphyria

Other Amyotrophic Lateral Sclerosis Drugs

Drug	Company	Phase	Status
Cell Therapy for ALS	INCELL	Unknown	Active
ALS Research	GliaPharm	Research	Active
ALS Disease Model Service	NeuroProof	Pre-clinical	Active
ALS Biomarker Program	Linus Biotechnology	Pre-clinical	Active
ALS Program	Biorchestra	Preclinical	Active
Program(s) for ALS	AviadoBio	Pre-clinical	Active
TCD601 for ALS	ITB Med	Phase 2	Active
ILB® for ALS	TikoMed	Phase 2	Active
ALS Patient-Led Research Initiative	BGI	Research	Active
ALS Pathway Discovery	Anima Biotech	Preclinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active
Foralumab (intranasal)	Tiziana Life Sciences	Phase 2	Planned (2H 2025)